ProKidney Corporation (PROK)

I expect that the next Pop will come when positive results are released from trials in November- see last PR regarding upcoming Poster Presentations. Not sure of the current short interest, but there useally is a decent size short position here, so that might help accelerate the Pop, with the right news

Is this one due for Pop #2? Catalysts? I don't know how much it matters,just curious has there been much dilution since July?

$PROK The gift that keeps on giving

Can anyone explain today's strength into the close?

For sure, self included.   Excellent action here! GL

Some profit taking today. I think we get back into the $3s next week.

prok.............................................................https://stockcharts.com/h-sc/ui?s=prok&p=W&b=5&g=0&id=p86431144783

Nice squeeze. PROK daily

Simple chart read puts it around $3.25-$3.50 short term if bullish trend continues

Broke it in a big way. Trials and discussions with FDA must be going well!

Nice to see it finally break its downtrend

Testing, testing- is anyone out there? Looks like there's a leak somewhere.

Still adding, said the tree falling in the woods.

I think it holds- I have been adding "trading shares" on every dip. $PROK is the gift that keeps giving.

Cracks under $2 or holds the line?

How much do you love $PROK?

From July 15th
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
• FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and
type 2 diabetes
• FDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and for full approval
• Nearly half of the patients required for the accelerated approval analysis using eGFR slope have been enrolled
• Topline data to support an application for accelerated approval is anticipated in Q2 2027
WINSTON-SALEM, N.C., July 15, 2025 – ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular
therapeutics company focused on chronic kidney disease (CKD), today announced confirmation of alignment with the U.S. Food and Drug
Administration (FDA) on the accelerated approval pathway for rilparencel. Rilparencel is an autologous cellular therapy that received Regenerative
Medicine Advanced Therapy (RMAT) designation from the FDA and currently is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1)
trial to demonstrate the therapy’s potential to preserve kidney function in patients with advanced CKD and type 2 diabetes.
In a recent Type B meeting, the FDA confirmed that the slope of estimated glomerular filtration rate (eGFR) in patients from the ongoing Phase 3
PROACT 1 study can serve as the surrogate endpoint and primary basis for a Biologics License Application (BLA) submission of rilparencel under the
accelerated approval pathway. The FDA agreed that a rilparencel effect size (versus sham controls) of at least 1.5 mL/min/1.73m2/year improvement
would be an acceptable demonstration of efficacy in the setting of patients receiving appropriate standard of care therapies. ProKidney anticipates
topline data readout of eGFR slope as the surrogate endpoint to support an application for accelerated approval in Q2 2027. To date, ProKidney has
enrolled nearly half of the patients required for the accelerated approval analysis. The FDA also confirmed that the ongoing Phase 3 PROACT 1 study
may serve as the confirmatory study to support full approval of rilparencel based on the primary time-to-event composite endpoint specified in the
protocol. Updated guidance on the expected timing of the confirmatory readout will be provided in 1H 2026.
“We are very encouraged by the FDA’s support of the accelerated approval pathway for rilparencel using eGFR slope, marking a critical regulatory
milestone for ProKidney,” said Bruce Culleton, M.D., CEO of ProKidney. “This alignment allows us to move forward with clarity and conviction as we
advance enrollment in our pivotal Phase 3 PROACT 1 study on the heels of the positive Phase 2 REGEN-007 topline results announced last week. We
look forward to our ongoing dialogue with the FDA, under RMAT designation, to bring rilparencel to patients with advanced CKD and diabetes, a
patient population with high unmet clinical and societal needs.”
About Chronic Kidney Disease
CKD is a progressive condition characterized by the gradual decline of kidney function, which can ultimately lead to end-stage kidney disease (ESKD)
requiring dialysis or transplantation. An estimated 37 million adults in the U.S. have CKD, though many remain undiagnosed in the early stages.
Diabetes is the leading cause of CKD, and individuals with both conditions face significantly elevated risks of cardiovascular events, hospitalization,
and mortality. ProKidney is developing rilparencel for patients with Stage 3b/4 CKD and diabetes, a population that includes 1 to 2 million people in the
U.S. While current treatment options aim to slow disease progression, there remains a substantial unmet need for therapies that can stabilize kidney
function and delay or prevent the need for dialysis in patients with advanced CKD.
About the Phase 3 REGEN-006 (PROACT 1) Clinical Trial
REGEN-006 is an ongoing Phase 3, randomized, blinded, sham controlled safety and efficacy study of rilparencel in subjects with advanced CKD and
type 2 diabetes. The study protocol was amended in 1H 2024 to focus on a subset of patients with Stage 4 CKD (eGFR 20-30 mL/min/1.73m2) and late
Stage 3b CKD (eGFR 30-35 mL/min/1.73m2) with accompanying albuminuria (UACR less than 5,000 mg/g for patients with eGFR 20-30
mL/min/1.73m2 and 300-5,000 mg/g for patients with eGFR 30-35 mL/min/1.73m2). The total planned enrollment is approximately 685 subjects.
Subjects are randomized (1:1) to the treatment group and the sham control group prior to kidney biopsy or a sham biopsy procedure, respectively. The
primary objective is to assess the efficacy of up to two rilparencel injections (one in each kidney) using a minimally invasive percutaneous approach.
The surrogate endpoint for accelerated approval is eGFR slope, and the primary composite endpoint is the time from first injection to the earliest of: at
least 40% reduction in eGFR; eGFR

Not a problem- they announced huge news this am on accelerated approval pathway with FDA

and now its running pre mkt.

Looks like the ATM offering put an end to PROK’s run today, IMO. They should’ve waited until after the earnings call—but instead, it seems they wanted to show a stronger cash position during the call.

massive bid at 3.81

cool.

Cashed out 80% of long position during the mayhem, taking little bites/adding here for the accumulation of Trading Shares as this heads back to $7 or above.

i grabbed some on the dip.

It's like a dream.

Where will it go today?

Pre-market and after hours are always deceptive

Where do you guys think the stock will close today, including after-hours?

Given the pre-market volume, I never expected it to stabilize between $4.50 and $4.70 today.

It's not for the faint of heart, but it does have something to offer for both traders and long-term investors. And shorts play their part too. Some will make bank on volatility, but without a big short position, you can't get a squeeze like we got yesterday.

Shorts got roasted.

Nice. Waiting for the dust to settle. Still some excellent catalysts this summer for PROK. Thinking she'll see plenty of volatility.

$PROK: $0.60prem made on those put-contracts.... now $1.40

Biggggggggggg loads tell the story.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176414318

GO $PROK puts

..

..

There appears to be a cup and handle pattern developing.

loaded 5.40

who cares

muted

$PROK: Big load on 7/18 $2.50 Puts

Now at $0.80 prem

Joining in on these


GO $PROK puts

go PROK, Not Broke

6.07

$PROK over $7 I like my post yesterday "don't loose your shorts" with the PROK weekly chart showing under the $ up to $14.

Anyways, took off more @ $7. And now I'm almost out of shares.

Citi's Price Target Update (July 8, 2025)

Citi raised its price target from $6 to $9, maintaining a Buy rating.
The upgrade follows positive Phase 2 REGEN-007 trial data, which exceeded expectations.
Citi also revised the program's probability of success upward to 60%, citing strong efficacy and the company’s healthy liquidity (~11× current ratio)

Citi's price target raise (from $6-$9) should help keep the momo going for a while.

Still have some .85's left. I've been left in the dust enough to control at lease some core position. But I've also seen these drop like a rock. This isn't one of those China stocks that do exactly that. We'll see.
GLTA

keep in mind, they….

…

halted this a gazillion times, during regular hours yesterday, but at least, during off hours, they cant do that.

💥 $1.30 to $6.18 in 15 Hours — Let’s Build a Serious Trader Network

PROK just hit $6.18, and I’m holding from an average of $1.30 — that’s a +375% gain in 15 hours. This wasn’t random. It was a calculated entry, heavy volume confirmation, and perfect execution.

I have a profitable biotech company that’s undervalued, and under the radar. Lining things up for next week.

If you’re serious about catching these early — not chasing, but catching — I’m building a tight group of traders who want to share setups like this before the breakout.

If you’re watching this move and thinking “I need in on the next one,” DM me.

🚫 No paid pumps
🚫 No Discord spam
✅ Just clean setups and smart momentum

Let’s catch the next winner — together.

I couldn't resist taking a bit more off. Crazy

Interesting PROK new dvlpments. @$6.20

wow, look at her gooooo!!

looking good pre market.